Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
Increasingly, clinical trials for Alzheimer’s disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology. However, making such a pre-clinical AD diagnosis is relatively costly and th...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Published: |
IOS Press
2016
|